BioLineRX Ltd. · TASE:BLRX
BioLineRX — Investor Presentation (December 2012)
31 slides from BioLineRX's investor presentation, December 2012

Slide 1: Company Presentation
Company Presentation December 2012

Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements.“ These statements represent BioLineRx’s expectations or beliefs regarding future events and may include words like "may," "expects," "believes," “plans,” “scheduled," and "intends,". These forward-looking statements i

Slide 3: BioLineRx Highlights
BioLineRx Highlights • 6 clinical stage assets, 2 in advanced clinical stages for large market indications • Broad pre-clinical pipeline – providing multiple opportunities for next generation clinical projects • Special strategic relationships and access to Israeli technology • Unique government-spo

Slide 4: Management
Management • Kinneret Savitsky, Ph.D., Chief Executive Officer – Chief Executive Officer since 2010 – General Manager of BioLine Innovations Jerusalem from 2004 through 2009 – Previously, Vice President of Biology at Compugen Ltd. (NASDAQ: CGEN) • Philip Serlin, CPA, MBA, Chief Financial and Operati

Slide 5: Management (cont.)
Management (cont.) • Leah Klapper, PhD, General Manager, BioLine Innovations Jerusalem – General Manager of BioLine Innovations Jerusalem since 2010 – VP of Pre-Clinical Development at BioLine Innovations Jerusalem from 2004 to 2009 – Previously, Vice President of Research and Development at CureTec

Slide 6: Our Business Model
Our Business Model Identify promising Conduct Feasibility Develop through Partner projects Testing` human POC • Strong scientific • Validate results of • Accelerated basis • Continued clinical inventors development development • High chance of • Resolve main program regulatory approval • Regulatory

Slide 7: Our Project Infrastructure Support
Our Project Infrastructure Support Expert Medical and Project Clinical Team Managers BD In-licensing and Pre-Clinical Out-licensing Team Multiple Projects Chemistry Team (Organic, Analytical, Intellectual Bioanalytical, Property Experts Formulation) Regulatory Affairs Team 7

Slide 8: Current Pipeline
Current Pipeline BL-1020 Schizophrenia Out-licensed to Cypress Bioscience in 2010; reacquired rights in 2011 BL-1040 AMI Out-licensed to Ikaria, Inc. following completion of Phase //iI BL-5010 Skin lesions BL-7040 Inflammatory bowel disease (IBD) BL-8040 AML & other hematological cancers BL-1021 Neu

Slide 9: BL-1020: First-in-Class GABA-Enhanced Anti-Psychotic for Schizophrenia
BL-1020: FIRST- IN- CLASS GABA-ENHANCED ANTI-PSYCHOTIC FOR SCHIZOPHRENIA

Slide 10: BL-1020 First In Class GABA Enhanced Anti-Psychotic
BL-1020 First In Class GABA Enhanced Anti- Psychotic • Indication: Schizophrenia; Cognitive Improvement in Schizophrenia (CIS) • Mode of Action: – Dopamine antagonism – GABAergic activity (associated with improved cognition) • Status: Phase II/III • Product Highlights: – First drug to show cognitive

Slide 11: Schizophrenia Market and Unmet Medical Need
Schizophrenia Market and Unmet Medical Need • Chronic, severe, and disabling brain disorder affecting ~1% of the U.S. adult population (National Institute of Mental Health) • Antipsychotic market estimated at $14 billion in US alone – Projected to stay stable through 2018 (DataMonitor) • Cognitive i

Slide 12: Phase 2b EAGLE Trial (Completed Sep 2009)
Phase 2b EAGLE Trial (Completed Sep 2009) Efficacy, safety and tolerability of BL-1020 in hospitalized patients with acute exacerbation of schizophrenia Main Trial Extension Trial BL-1020 BL-1020 10 mg/day 10 mg/day BL-1020 BL-1020 20-30 mg/day 20-30 mg/day Risperidone Risperidone 2-8 mg/day 2-8 mg/

Slide 13: Evidence for BL-1020's Pro-Cognitive Effects in EAGLE Trial
Evidence for BL-1020's Pro-Cognitive Effects in EAGLE Trial * BL-1020 BL-1020 Risperidone Placebo 10mg 20-30mg C BLOB 13

Slide 14: LS Mean Change of BACS Subscores (Age - Gender -Corrected)
Improvement Demonstrated on all BACS Subscales Change in BACS Subscores from Baseline to Week 6 14 LS Mean Change of BACS Subscores 12 (Age - Gender -Corrected) BL-1020 10 mg 10 BL-1020 20-30 mg 8 Risperidone Placebo 6 4 2 0 Verbal Memory Digit Sequency Token Motor Verbal Fluency Symbol Coding Tower

Slide 15: Impact of Consistent vs. Inconsistent Timing of Neurocognitive Assessments
Impact of Consistent vs. Inconsistent Timing of Neurocognitive Assessments on Signal Detection Abstract and poster for the International Society for CNS Clinical Trials and Methodology (ISCTM) conference Oct 2012 Cognitive functioning is influenced by circadian rhythms (i.e., 24-hour time cycle) ove

Slide 16: CLARITY Phase II/III Trial (Commenced June 11)
CLARITY Phase II/III Trial (Commenced June 11) Acute and chronic antipsychotic and cognitive efficacy, safety and tolerability of BL-1020 compared with Risperidone Acute Chronic Phase Phase BL-1020 Titrate to MTD (15-35) BL-1020 Risperidone Titrate to MTD (2-6) Risperidone Up to 450 patients Primary

Slide 17: BL-1040: First-in-Class Myocardial Implant for Prevention of Cardiac Remodeling
BL-1040: FIRST-IN-CLASS MYOCARDIAL IMPLANT FOR PREVENTION OF CARDIAC REMODELING FOLLOWING AMI Out-licensed to Ikaria Inc. and being developed as Bioabsorbable Cardiac Matrix (BCM)

Slide 18: BL-1040: First-In-Class Myocardial Implant
BL-1040: First-In-Class Myocardial Implant for Prevention of Cardiac Remodeling Following AMI • Indication: Cardiac remodeling • Mode of Action: Provides support to ischemic tissue during healing • Status: CE Mark registration trial - conducted by Ikaria Inc. • Product highlights: • Resorbable polym

Slide 19: Current Treatment Methodologies and Unmet Medical Need
Current Treatment Methodologies and Unmet Medical Need Vessel occlusion Tissue damage Successfully treated with PCI and stents No sufficiently effective treatment for myocardial damage 19

Slide 20: How Does BL-1040 Work?
How Does BL-1040 Work? Infarct related artery (intra-vascular) injection Deposition into infarcted tissue Liquid to gel phase transition upon contact with infarcted tissue Phase transition at infarct area creates resorbable bioprosthetic scaffold providing mechanical support to damaged cardiac muscl

Slide 21: BL-1040 Deposits in Damaged Tissue Following Intra-Coronary Injection
BL-1040 Deposits in Damaged Tissue Following Intra-Coronary Injection Targeting mechanism: 1. Injection occurs in the infarct related artery 2. Capillary bed compromised secondary to ischemia allows inflow of BL-1040 3. Physiological condition of ischemic region enables liquid to gel transition BL-1

Slide 22: BL-1040 Prevents Structural Changes Following AMI
BL-1040 Prevents Structural Changes Following AMI Porcine AMI model, day 60 Dilated left Normal size ventricle left ventricle Normal LV Thin LV wall wall Untreated BL-1040 22

Slide 23: BL-1040 Safe and Well-Tolerated in Phase I/II Clinical Trial Results
BL-1040 Safe and Well-Tolerated in Phase I/II Clinical Trial Results • Clinical program based on extensive interaction with FDA (CDRH division) • Phase I/II pilot study in Europe – completed January 2010 – 27 patients, safety and preliminary efficacy in patients with primary MI at high risk for LV r

Slide 24: Ikaria BL-1040 Out-Licensing Transaction
Ikaria BL-1040 Out-Licensing Transaction • Ikaria - proven expertise in drug and medical device development and singular focus on acute care • Terms: √ $7 million upfront √ $10 million first milestone – ~$115 million in additional regulatory and developmental milestones – ~$150 million in commercial

Slide 25: BL-1040 Active Trial Program: Current Status and Next Steps
BL-1040 Active Trial Program: Current Status and Next Steps Two pivotal trials: CE Mark Registration trial Second Pivotal trial for US approval − Trial commenced − Final discussions with FDA − Overall design: − Overall design: • Placebo controlled • Placebo controlled • 306 patients • >1,000 patient

Slide 26: BioLineRx's Other Main Programs
BioLineRx’s Other Main Programs • BL-7040 for inflammatory bowel disease – Successfully completed Phase I study – Phase II ongoing, results expected by early 2013 • BL-8040 for acute myeloid leukemia/other hematological cancers – Successfully completed Phase I study – Phase II clinical study expecte

Slide 27: Unique Funding Programs
Unique Funding Programs BioLine Innovations Jerusalem • Only Israeli biotech incubator supported by Office of Chief Scientist, Israeli Trade Ministry (OCS) – $13 million received, plus additional $5 million under regular OCS funding track – Enhanced financial support, up to 85% of first $2 million o

Slide 28: Financial Summary
Financial Summary • Available cash as of September 30, 2012 - ~$26 million − Annual burn rate between $15-18 million − Cash expected to last into Q1 2014 (w/o additional funding or revenues) • Number of employees - ~50 • Capital structure (on basis of ADSs) − 18.0 million outstanding – basic capital

Slide 29: Analyst Coverage
Analyst Coverage BioLineRx Ltd. is followed by the analysts listed below: Analyst Firm Raghuram Selvaraju Aegis Capital Corp. Steven Tepper Harel Finance Robert Hazlett Roth Capital Partners, LLC Please note that any opinions, estimates or forecasts regarding BioLineRx Ltd.'s performance made by the

Slide 30: Expected Company Milestones in Next 12-18 Months
Expected Company Milestones in Next 12-18 Months BL-1020 - Schizophrenia BL-8040 – Hematological Cancers • Recruitment milestones • Start of Phase II trial H1 2013 • Interim results in Q1 2013 • Interim results expected end 2013 • Final results expected H2 2013 BL-5010 – Skin Lesions • Partnering tr

Slide 31: Bench1o Bedrideto Fatner
Bench1o Bedrideto Fatner £7 2 4 fH _ BIiIOLINE ><
Source: Internet Archive copy of biolinerx.com
More decks from BioLineRX Ltd.
Investor Presentation (July 2026)39 slides · July 2026
Q1 2026 Earnings Presentation28 slides · May 27, 2026
Technical Presentation (December 2020)14 slides · Dec 16, 2020
Technical Presentation (December 2020)49 slides · Dec 16, 2020
Investor Presentation (February 2019)31 slides · Feb 4, 2019
Investor Presentation (October 2018)30 slides · Oct 1, 2018